The regulations will come into force November 1, 2018
OTTAWA, Aug. 9, 2018/CNW/ - The Government of Canada recognizes that medical assistance in dying is a deeply personal issue for all Canadians and must be addressed with the utmost compassion and empathy. It is critically important to monitor
Today, the Government of Canada published final regulations in Canada Gazette, Part II that create a federal pan-Canadian monitoring system on medical assistance in dying. The regulations set out reporting requirements for physicians and nurse practitioners who receive written requests for medical assistance in dying, and for pharmacists who dispense medication for assisted dying. Any personal data collected will be protected under the federal Privacy Act.
The information will be used to publish annual reports on medical assistance in dying in Canada, including the number of requests received, the number of medically assisted deaths and the number of people found ineligible. The regulations come into force on November 1, 2018, and providers have until that date to become familiar with the new reporting requirements.
Health Canada expects to continue to produce interim reports until the permanent monitoring and reporting system is operational. Annual federal reporting using the data collected under the Regulations is expected to begin in 2019.
"Medical assistance in dying is a sensitive, complex issue and many Canadians have deeply-held views on the subject. We are committed to ensuring that Canadians who choose medical assistance in dying have access to these services. These regulations promote transparency and will help us monitor how this service is being implemented across the country."
The Honourable Ginette Petitpas TaylorMinister of Health
SOURCE Health Canada
Subscribe to our Free Newsletters!
Collagen plays a crucial role in glowing skin, strong nails and shiny hair. You can boost collagen ...
CRISPR technology is a simple but potent tool for editing any part of the genome (complete set of ...
FDA recently approved Mogamulizumab-kpkc, a human monoclonal antibody prescribed for adult ...View All